An official website of the United States government
As our population ages, neurological impairments and degeneration of the musculoskeletal system yield gait abnormalities, which can significantly reduce quality of life. Gait rehabilitative therapy has been widely adopted to help patients maximize community participation and living independence. To further improve the precision and efficiency of rehabilitative therapy, more objective methods need to be developed based on sensory data. In this paper, an algorithmic framework is proposed to provide classification of gait disorders caused by two common neurological diseases, stroke and Parkinson's Disease (PD), from ground contact force (GCF) data. An advanced machine learning method, multi-task feature learning (MTFL), is used to jointly train classification models of a subject's gait in three classes, post-stroke, PD and healthy gait. Gait parameters related to mobility, balance, strength and rhythm are used as features for the classification. Out of all the features used, the MTFL models capture the more important ones per disease, which will help provide better objective assessment and therapy progress tracking. To evaluate the proposed methodology we use data from a human participant study, which includes five PD patients, three post-stroke patients, and three healthy subjects. Despite the diversity of abnormalities, the evaluation shows that the proposed approach can successfully distinguish post-stroke and PD gait from healthy gait, as well as post-stroke from PD gait, with Area Under the Curve (AUC) score of at least 0.96. Moreover, the methodology helps select important gait features to better understand the key characteristics that distinguish abnormal gaits and design personalized treatment.
more »
« less
Multi-View Graph Convolutional Network and Its Applications on Neuroimage Analysis for Parkinson's Disease
Parkinson's Disease (PD) is one of the most prevalent neurodegenerative diseases that affects tens of millions of Americans. PD is highly progressive and heterogeneous. Quite a few studies have been conducted in recent years on predictive or disease progression modeling of PD using clinical and biomarkers data. Neuroimaging, as another important information source for neurodegenerative disease, has also arisen considerable interests from the PD community. In this paper, we propose a deep learning method based on Graph Convolutional Networks (GCN) for fusing multiple modalities of brain images in relationship prediction which is useful for distinguishing PD cases from controls. On Parkinson's Progression Markers Initiative (PPMI) cohort, our approach achieved 0.9537±0.0587 AUC, compared with 0.6443±0.0223 AUC achieved by traditional approaches such as PCA.
more »
« less
- Award ID(s):
- 1718798
- PAR ID:
- 10110528
- Date Published:
- Journal Name:
- AMIA ... Annual Symposium proceedings
- ISSN:
- 1559-4076
- Page Range / eLocation ID:
- 1147-1156
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Parkinson's Disease (PD) impacts millions globally, causing debilitating motor symptoms. While Closed-Loop Deep Brain Stimulation (CL-DBS) has emerged as a promising treatment, existing systems often suffer from high energy consumption, making them impractical for wearable or implantable devices. This research introduces an innovative neuromorphic approach to enhance CL-DBS performance, utilizing Leaky Integrate-and-Fire (LIF) neuron-based controllers to adaptively modulate stimulation signals based on symptom severity. Two controllers, the on-off LIF and dual LIF models, are proposed, achieving significant reductions in power consumption by 19% and 56%, respectively, while enhancing suppression efficiency by 4.7% and 6.77%. Additionally, this work addresses the scarcity of datasets for PD symptoms by developing a novel dataset featuring neural activity from the subthalamic nucleus (STN), incorporating beta oscillations as key physiological biomarkers. This dataset aims to support further advancements in neuromorphic CL-DBS systems and is openly shared with the research community. By combining energy-efficient neuromorphic controllers with a comprehensive dataset, this study not only advances the technological feasibility of CL-DBS systems for PD treatment but also provides a foundation for personalized and adaptive neuromodulation therapies, paving the way for improved quality of life for individuals with Parkinson's Disease.more » « less
-
Abstract Early diagnosis of Alzheimer’s disease plays a pivotal role in patient care and clinical trials. In this study, we have developed a new approach based on 3D deep convolutional neural networks to accurately differentiate mild Alzheimer’s disease dementia from mild cognitive impairment and cognitively normal individuals using structural MRIs. For comparison, we have built a reference model based on the volumes and thickness of previously reported brain regions that are known to be implicated in disease progression. We validate both models on an internal held-out cohort from The Alzheimer's Disease Neuroimaging Initiative (ADNI) and on an external independent cohort from The National Alzheimer's Coordinating Center (NACC). The deep-learning model is accurate, achieved an area-under-the-curve (AUC) of 85.12 when distinguishing between cognitive normal subjects and subjects with either MCI or mild Alzheimer’s dementia. In the more challenging task of detecting MCI, it achieves an AUC of 62.45. It is also significantly faster than the volume/thickness model in which the volumes and thickness need to be extracted beforehand. The model can also be used to forecast progression: subjects with mild cognitive impairment misclassified as having mild Alzheimer’s disease dementia by the model were faster to progress to dementia over time. An analysis of the features learned by the proposed model shows that it relies on a wide range of regions associated with Alzheimer's disease. These findings suggest that deep neural networks can automatically learn to identify imaging biomarkers that are predictive of Alzheimer's disease, and leverage them to achieve accurate early detection of the disease.more » « less
-
null (Ed.)Abstract The ability to measure total and phosphorylated tau levels in clinical samples is transforming the detection of Alzheimer’s disease (AD) and other neurodegenerative diseases. In particular, recent reports indicate that accurate detection of low levels of phosphorylated tau (p-tau) in plasma provides a reliable biomarker of AD long before sensing memory loss. Therefore, the diagnosis and monitoring of neurodegenerative diseases progression using blood samples is becoming a reality. These major advances were achieved by using antibodies specific to p-tau as well as sophisticated high-sensitivity immunoassay platforms. This review focuses on these enabling advances in high-specificity antibody development, engineering, and novel signal detection methods. We will draw insights from structural studies on p-tau antibodies, engineering efforts to improve their binding properties, and efforts to validate their specificity. A comprehensive survey of high-sensitivity p-tau immunoassay platforms along with sensitivity limits will be provided. We conclude that although robust approaches for detecting certain p-tau species have been established, systematic efforts to validate antibodies for assay development is still needed for the recognition of biomarkers for AD and other neurodegenerative diseases.more » « less
-
Abstract There are currently no effective biomarkers for diagnosing Parkinson’s disease (PD) or tracking its progression. Here, we developed an artificial intelligence (AI) model to detect PD and track its progression from nocturnal breathing signals. The model was evaluated on a large dataset comprising 7,671 individuals, using data from several hospitals in the United States, as well as multiple public datasets. The AI model can detect PD with an area-under-the-curve of 0.90 and 0.85 on held-out and external test sets, respectively. The AI model can also estimate PD severity and progression in accordance with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale ( R = 0.94, P = 3.6 × 10 –25 ). The AI model uses an attention layer that allows for interpreting its predictions with respect to sleep and electroencephalogram. Moreover, the model can assess PD in the home setting in a touchless manner, by extracting breathing from radio waves that bounce off a person’s body during sleep. Our study demonstrates the feasibility of objective, noninvasive, at-home assessment of PD, and also provides initial evidence that this AI model may be useful for risk assessment before clinical diagnosis.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Conference Paper:
- The DOI is not currently available.
